摘要
目的分析唑来膦酸钠联合鲑鱼降钙素治疗老年原发性骨质疏松症的疗效。方法82例老年原发性骨质疏松症患者,根据随机双盲法分为对照组和分析组,每组41例。对照组应用鲑鱼降钙素联合钙剂治疗,分析组在对照组的基础上加用唑来膦酸钠治疗。比较两组患者的治疗效果、腰椎骨密度、生活质量、不良反应发生情况。结果分析组患者治疗总有效率为95.1%,高于对照组的78.0%,差异具有统计学意义(P<0.05)。治疗后,分析组患者腰椎骨密度(0.779±0.130)g/cm^2明显高于对照组的(0.630±0.110)g/cm^2,差异具有统计学意义(P<0.05)。治疗后,分析组患者心理、躯体评分明显高于对照组,差异具有统计学意义(P<0.05)。分析组患者不良反应发生率为4.9%(2/41),低于对照组的19.5%(8/41),差异具有统计学意义(P<0.05)。结论对老年原发性骨质疏松症患者应用唑来膦酸钠联合鲑鱼降钙素治疗可取得很好的疗效,能有效改善其骨密度和生活质量,且治疗安全性较高。
Objective To analyze the efficacy of zoledronic acid sodium combined with salcatonin in the treatment of senile primary osteoporosis.Methods A total of 82 senile patients with primary osteoporosis were divided into control group and analysis group according to random double-blind method,with 41 cases in each group.The control group was treated with salcatonin combined with calcium,and the analysis group was treated with zoledronic acid sodium on the basis of the control group.The therapeutic effect,lumbar spine bone density,quality of life,occurrence of adverse reactions were compared between the two groups.Results The total treatment effective rate of analysis group was 95.1%,which was higher than 78.0%of the control group,and the difference was statistically significant(P<0.05).After treatment,lumbar spine bone density(0.779±0.130)g/cm^2 of analysis group was obviously higher than(0.630±0.110)g/cm^2 of the control group,and the difference was statistically significant(P<0.05).After treatment,the psychological and physical scores of analysis group were obviously higher than those of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions of analysis group was 4.9%(2/41),which was lower than 19.5%(8/41)of the control group,and the difference was statistically significant(P<0.05).Conclusion Zoledronate sodium combined with salcatonin can achieve a good effect in the treatment of senile patients with primary osteoporosis,and can effectively improve their bone density and quality of life with higher safety.
作者
王海英
WANG Hai-ying(Department of Endocrinology,Chaoyang Second Hospital,Chaoyang 122000,China)
出处
《中国现代药物应用》
2020年第22期8-10,共3页
Chinese Journal of Modern Drug Application
